SCHEMBL476619

SCHEMBL476619

Cc1cc2ccc(Cl)c(Cl)c2n1CCCNS(C)(=O)=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.39
TLR7 Q9NYK1 1/20 0.35
POLB P06746 3/20 0.35
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.34
USP2 O75604 1/20 0.34
ESR1 P03372 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CASP1 P29466 1/20 0.34
CYP2C19 P33261 1/20 0.34
CNR2 P34972 1/20 0.34
TDP1 Q9NUW8 2/20 0.34
MAPT P10636 2/20 0.34
KCNJ5 P48544 1/20 0.34
KCNJ3 P48549 1/20 0.34
FGB P02675 1/20 0.33
PLK1 P53350 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL476675 0.87 LMNA (0.34) ALDH1A1POLBKMT2AMEN1USP2
SCHEMBL476604 0.85 RECQL (0.41) ALDH1A1TLR7POLBKMT2AMEN1
SCHEMBL476594 0.81 ALDH1A1 (0.37) ALDH1A1TLR7POLBKMT2AMEN1
SCHEMBL476637 0.80 ALDH1A1 (0.39) ALDH1A1TLR7POLBKMT2AMEN1
SCHEMBL5673232 0.78 HTR2A (0.35) ALDH1A1KMT2AMEN1MAPT
SCHEMBL476681 0.78 MEN1 (0.39) ALDH1A1TLR7POLBKMT2AMEN1
SCHEMBL476538 0.78 SMN1; SMN2 (0.40) ALDH1A1TLR7POLBKMT2AMEN1
SCHEMBL476708 0.77 HTT (0.46) ALDH1A1TLR7POLBKMT2AMAPT
SCHEMBL476636 0.76 HTR7 (0.39) ALDH1A1POLBKMT2AMEN1USP2
SCHEMBL20504942 0.74 HTR2A (0.36) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1951225-B1 3-ACYLINDOLE DERIVATIVES THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI SA (FR) 2012-02-01 EP disclosed
US-7741363-B2 3-Acylindole derivatives, preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2010-06-22 US disclosed
EP-1567150-B1 DERIVATIVES OF INDOLE-3-CARBOXAMIDE, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS SANOFI AVENTIS (FR) 2009-08-12 EP disclosed
US-20080275102-A1 3-ACYLINDOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2008-11-06 US disclosed
EP-1951225-A2 3-ACYLINDOLE DERIVATIVES THE PREPARATION AND THE THERAPEUTIC USE THEREOF sanofi-aventis (FR) 2008-08-06 EP disclosed
WO-2007057571-A2 3-ACYLINDOLE DERIVATIVES THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-05-24 WO disclosed
US-7202268-B2 Derivatives of indole-3-carboxamide, preparation method thereof and application of same in therapeutics SANOFI-AVENTIS (FR) 2007-04-10 US disclosed
US-7138424-B2 Indole derivatives, method for preparing same and pharmaceutical compositions containing same SANOFI-AVENTIS (FR) 2006-11-21 US disclosed
US-20060089345-A1 Indole derivatives, method for preparating same and pharmaceutical compositions containing same SANOFI-AVENTIS (FR) 2006-04-27 US disclosed
US-6995184-B2 Such as (7-chloro-2-methyl-1-(3-(methylsulphanyl)propyl)-1H-indol-3-yl)(2,3-dichloro-phenyl)methanone; cannabinoid receptors (cb2); G proteins coupled receptors SANOFI-AVENTIS (FR) 2006-02-07 US disclosed
US-20050288356-A1 Derivatives of indole-3-carboxamide, preparation method thereof and application of same in therapeutics SANOFI-AVENTIS (FR) 2005-12-29 US disclosed
EP-1507758-B1 INDOLE DERIVATIVES AND THEIR USE AS LIGANDS FOR CB2 RECEPTORS SANOFI AVENTIS (FR) 2005-11-02 EP disclosed
EP-1339679-B1 3-ARYLINDOLE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS SANOFI AVENTIS (FR) 2005-08-10 EP disclosed
EP-1507758-A2 INDOLE DERIVATIVES AND THEIR USE AS LIGANDS FOR CB2 RECEPTORS Sanofi-Aventis (FR) 2005-02-23 EP disclosed
US-20040034090-A1 3-Arylindole derivatives and their use as cb2 receptor agonists SANOFI-AVENTIS (FR) 2004-02-19 US disclosed
WO-2003097597-A2 INDOLE DERIVATIVES AND THE USE THEREOF AS CB2 RECEPTOR LIGANDS SANOFI-AVENTIS (FR) 2003-11-27 WO disclosed
EP-1339679-A1 3-ARYLINDOLE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS Sanofi-Aventis (FR) 2003-09-03 EP disclosed
WO-2002042269-A1 3-ARYLINDOLE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS SANOFI-SYNTHELABO (FR) 2002-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288356-A1 Derivatives of indole-3-carboxamide, preparation method thereof and application of same in therapeutics IDO1, IDO2, TDO2 ALDH1A1 955/4885TLR7 863/4885POLB 3916/4885
US-20040034090-A1 3-Arylindole derivatives and their use as cb2 receptor agonists CNR2, CNR1, GPR52 ALDH1A1 1071/4885TLR7 348/4885POLB 4844/4885
US-20060089345-A1 Indole derivatives, method for preparating same and pharmaceutical compositions containing same CNR2, CNR1, IDO2 ALDH1A1 2601/4885TLR7 716/4885POLB 4798/4885
US-20080275102-A1 3-ACYLINDOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF F12, ECI1, NQO2 ALDH1A1 182/4885TLR7 924/4885POLB 4291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.